Hermes Vector

Science

Experimental compound burns fat without muscle loss in mice

UC Berkeley researchers found TOFA increased energy expenditure by up to 18% in mice, reducing fat while preserving muscle, and enhanced results when combined with GLP-1 drugs.

By Hermes Vector

Checked against 2 sourcesScienceDailynews.ssbcrack.com
Illustration for: Experimental compound burns fat without muscle loss in mice

In brief

  • TOFA increased energy expenditure by up to 18% in mice without increased activity or higher body temperature.
  • Obese mice treated with TOFA lost fat without significant loss of lean muscle mass.
  • TOFA combined with semaglutide or tirzepatide produced greater benefits than either treatment alone in mice.
  • The compound has not been tested for safety or effectiveness in humans.

Experimental compound burns fat without muscle loss in mice

Researchers at the University of California, Berkeley, have identified an experimental compound that helped obese mice burn more energy and lose fat while largely preserving lean muscle, according to a study published in Science Advances and reported by ScienceDaily and SSBCrack News.

The compound, called 5-tetradecyloxy-2-furoic acid (TOFA), increased energy expenditure in mice by as much as 18%. The animals did not become more physically active, and their body temperature did not rise. Treatment was also associated with improved blood-sugar regulation, lower triglyceride levels and better measures of fatty liver disease.

How TOFA Works

TOFA inhibits enzymes that help the body produce fatty acids, while also activating two cellular receptors, PPARα and PPARδ. These receptors regulate genes involved in taking up and breaking down fat for energy. The researchers say this combination may help explain why the compound both limits the production of certain fats and encourages the body to use available fat as fuel.

"Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and the study’s senior author. "GLP-1s work almost entirely on the first, so we went after the second."

Combination With Existing Drugs

Current medicines such as Ozempic and Wegovy, which contain semaglutide, and Mounjaro and Zepbound, which contain tirzepatide, help many people lose weight by reducing appetite and food intake. But digestive side effects can make these drugs difficult for some patients to tolerate. Lower food consumption may also contribute to inadequate nutrition and loss of muscle, which can affect strength, mobility and health over time.

The researchers also tested TOFA alongside semaglutide and tirzepatide in mice. The combinations produced greater improvements in body weight, blood glucose, insulin levels and triglycerides than either treatment alone. The results suggest that a medicine that increases energy use could potentially complement drugs that suppress appetite.

"In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement," Näär said.

Human Trials Still Needed

The results are preliminary. They come from animal experiments, and further research is needed to establish whether TOFA has similar effects in people, what dose might be appropriate and whether it is safe. The study does not show that people taking existing weight-loss medications should use or seek out TOFA.

The Berkeley researchers have established a biotechnology company, ReRx Therapeutics, to support efforts to advance the work toward potential clinical applications. The research received discretionary funding from UC Berkeley, with additional support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

What is the name of the experimental compound and what university conducted the study?
The compound is called 5-tetradecyloxy-2-furoic acid (TOFA), and the study was conducted by researchers at the University of California, Berkeley.
How much did the compound increase energy expenditure in mice?
TOFA increased energy expenditure in mice by as much as 18%.
How does TOFA work at the cellular level?
TOFA inhibits enzymes that help the body produce fatty acids and activates two cellular receptors, PPARα and PPARδ, which regulate genes involved in taking up and breaking down fat for energy.
How did TOFA perform when combined with existing weight-loss drugs in mice?
The combinations of TOFA with semaglutide and tirzepatide produced greater improvements in body weight, blood glucose, insulin levels, and triglycerides than either treatment alone.
What is the name of the biotechnology company established to advance this research?
The Berkeley researchers have established a biotechnology company called ReRx Therapeutics to support efforts to advance the work toward potential clinical applications.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Science

Curiosity rover finds pure sulfur rocks on Mars

NASA's Curiosity rover cracked open a rock in Mars' Gediz Vallis channel and exposed yellow crystals of pure elemental sulfur, the first such detection on the planet.

Checked against 5 sourcesdw.comforo3d.comlatimes.com+2 more